Last reviewed · How we verify

Levomilnacipran Hydrochloride Extended-Release Capsules — Competitive Intelligence Brief

Levomilnacipran Hydrochloride Extended-Release Capsules (Levomilnacipran Hydrochloride Extended-Release Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Psychiatry / Neurology.

phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Levomilnacipran Hydrochloride Extended-Release Capsules (Levomilnacipran Hydrochloride Extended-Release Capsules) — Zhejiang Huahai Pharmaceutical Co., Ltd.. Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the brain by blocking their reuptake at the neuronal synapse.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Levomilnacipran Hydrochloride Extended-Release Capsules TARGET Levomilnacipran Hydrochloride Extended-Release Capsules Zhejiang Huahai Pharmaceutical Co., Ltd. phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET)
Pristiq Desvenlafaxine Succinate Pfizer marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin and norepinephrine reuptake 2008-01-01
Effexor Venlafaxine Hydrochloride Pfizer marketed Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Serotonin and norepinephrine reuptake transporters 1993-01-01
Effexor® (Venlafaxine) Effexor® (Venlafaxine) Wyeth is now a wholly owned subsidiary of Pfizer marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT); Norepinephrine transporter (NET)
venlafaxine (Effexor) venlafaxine (Effexor) National Institute of Mental Health (NIMH) marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT, weak)
Venlafaxine XR Venlafaxine XR Ministry of Health & Welfare, Korea marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT); Norepinephrine transporter (NET)
Duloxetine (Cymbalta) Duloxetine (Cymbalta) New York State Psychiatric Institute marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT); Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

  1. Pfizer · 3 drugs in this class
  2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
  3. National Institute of Mental Health (NIMH) · 2 drugs in this class
  4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
  5. Eli Lilly and Company · 2 drugs in this class
  6. New York State Psychiatric Institute · 1 drug in this class
  7. North Dakota State University · 1 drug in this class
  8. Ministry of Health & Welfare, Korea · 1 drug in this class
  9. Purdue Pharma, Canada · 1 drug in this class
  10. Shanghai Mental Health Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levomilnacipran Hydrochloride Extended-Release Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/levomilnacipran-hydrochloride-extended-release-capsules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: